Article Details
Retrieved on: 2024-04-27 16:45:01
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a trial for a personalized mRNA vaccine (mRNA-4157/V940) for melanoma, a type of skin cancer, combined with pembrolizumab (Keytruda), relating to cancer immunotherapy and utilizing RNA technology. Merck & Co. is involved in this innovative treatment. Steve Young, mentioned in the tags, represents a patient in the trial.
Article found on: www.adomonline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here